Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression

The wild-type (wt) p53 protein has transcriptional activation functions which may be linked to its tumor suppressor activity. Many mutant p53 proteins expressed in cancers have lost the ability to function as transcriptional activators and furthermore may inhibit wt p53 function. To study the mechanisms by which mutant forms of p53 have lost their transactivation function and can act in a dominant negative manner, a structure-function analysis of both mutant and engineered truncated forms of p53 was carried out. We show that different mutant p53 proteins found in cancers vary in the ability to inhibit the transcriptional transactivation and specific DNA binding activities of wt human p53. This transdominant effect was mediated through the carboxy-terminal oligomerization region. The role of the transactivation activity in transformation suppression by wt p53 was also examined by constructing an N-terminal deletion mutant lacking the transactivation domain. This mutant was unable to transactivate but could bind specifically to DNA. Although it was impaired in its ability to suppress transformation of primary rat embryo fibroblasts by adenovirus E1A plus activated ras, the N-terminal deletion mutant still had some suppression activity, suggesting that additional functions of p53 may contribute to transformation suppression.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  C. Finlay,et al.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.

[3]  P. Howley,et al.  The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein. , 1992, The EMBO journal.

[4]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[5]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[6]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[7]  M. Subler,et al.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.

[8]  E. Appella,et al.  Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Friedman,et al.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.

[10]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[11]  M. Remm,et al.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. , 1992, Oncogene.

[12]  S. Friend,et al.  Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[14]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[15]  A. Levine,et al.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.

[16]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[17]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[18]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Berk,et al.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein , 1992, Nature.

[20]  R. Iggo,et al.  Mammalian p53 can function as a transcription factor in yeast. , 1992, Nucleic acids research.

[21]  T. Unger,et al.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. , 1992, The EMBO journal.

[22]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[23]  L. Tsai,et al.  Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F , 1992, Nature.

[24]  G. Lozano,et al.  Analysis of p53 mutants for transcriptional activity , 1991, Molecular and cellular biology.

[25]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Rotter,et al.  Involvement of wild-type p53 in pre-B-cell differentiation in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  V. Rotter,et al.  A DNA binding domain is contained in the C-terminus of wild type p53 protein. , 1991, Nucleic acids research.

[28]  U. Santhanam,et al.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[30]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[31]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[32]  S. Tapscott,et al.  The MCK enhancer contains a p53 responsive element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[34]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[35]  C. Dang,et al.  A potential transcriptional activation element in the p53 protein. , 1990, Oncogene.

[36]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[37]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[38]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[39]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[40]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[41]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[42]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[43]  T. Soussi,et al.  Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70 , 1989, Journal of virology.

[44]  W. Schaffner,et al.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.

[45]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[46]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[47]  M. Oren,et al.  Oligomerization of oncoprotein p53 , 1988, Journal of virology.

[48]  J. Nevins,et al.  Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element , 1983, Cell.

[49]  B. Howard,et al.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.

[50]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[51]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[52]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[53]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.

[54]  J. E. Stenger,et al.  Formation of stable p53 homotetramers and multiples of tetramers , 1992, Molecular carcinogenesis.

[55]  J. Minna,et al.  Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. , 1992, Oncogene.